Curis (NASDAQ:CRIS) Trading 5.4% Higher

Curis, Inc. (NASDAQ:CRIS)’s stock price traded up 5.4% during trading on Thursday . The stock traded as high as $1.96 and last traded at $1.96, 165,700 shares traded hands during trading. A decline of 55% from the average session volume of 372,102 shares. The stock had previously closed at $1.86.

Separately, ValuEngine lowered Curis from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th.

The company has a 50 day simple moving average of $2.10 and a 200 day simple moving average of $1.69.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). The firm had revenue of $2.09 million for the quarter. Curis had a negative return on equity of 729.52% and a negative net margin of 307.75%.

A number of large investors have recently made changes to their positions in CRIS. Morgan Stanley raised its position in shares of Curis by 155.6% during the 2nd quarter. Morgan Stanley now owns 19,564 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 11,911 shares during the period. BlackRock Inc. raised its position in shares of Curis by 15.2% during the 2nd quarter. BlackRock Inc. now owns 487,816 shares of the biotechnology company’s stock worth $908,000 after purchasing an additional 64,262 shares during the period. Renaissance Technologies LLC raised its position in shares of Curis by 20.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,191,419 shares of the biotechnology company’s stock worth $2,216,000 after purchasing an additional 203,590 shares during the period. Cetera Advisor Networks LLC acquired a new stake in shares of Curis during the 2nd quarter worth approximately $42,000. Finally, Fosun International Ltd raised its position in shares of Curis by 46.6% during the 2nd quarter. Fosun International Ltd now owns 581,834 shares of the biotechnology company’s stock worth $1,065,000 after purchasing an additional 184,965 shares during the period. Institutional investors own 22.47% of the company’s stock.

Curis Company Profile (NASDAQ:CRIS)

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.